The short version.
AOD-9604 is a 16-amino-acid synthetic peptide derived from the C-terminal end of human growth hormone (residues 177-191). The original premise, developed in the late 1990s at Monash University, was simple: isolate the part of the GH molecule that drives lipolysis (fat breakdown) without the parts that drive insulin resistance, IGF-1 elevation, or growth of non-fat tissue. It's the reason people search for it as part of a body recomposition protocol — they want the fat-loss angle of GH without the broader hormonal weight.
Mechanistically, AOD-9604 is thought to interact with beta-3 adrenergic receptors and stimulate lipolysis in adipocytes. It does not bind the GH receptor in the same way full-length GH does, which is why the original development pitch was "the fat-burning fragment without the GH side effects."
What the literature actually says.
This is where honesty matters. AOD-9604 went through Phase IIb obesity trials in the mid-2000s. The Phase IIb trial in obese adults — published in 2007 — found AOD-9604 was well tolerated but did not produce statistically significant weight loss versus placebo at 12 weeks. The compound was subsequently dropped from obesity development.
Australia's Therapeutic Goods Administration later allowed AOD-9604 to be used in compounded products, and the compound remained available through compounding pharmacies. That regulatory path is not the same as FDA approval. As of 2026, AOD-9604 is not an FDA-approved drug for any indication, and its use in the U.S. is via compounding under physician prescription.
The animal data on lipolysis is more positive than the human obesity trial. That's a common pattern with metabolic peptides and worth taking seriously: rodent fat-loss results frequently fail to translate to humans at the doses and durations studied.
The fragment hypothesis was elegant. The Phase IIb obesity trial didn't separate from placebo. That tension is the whole story.
Why oversight matters.
The internet sells almost any peptide as research chemicals — vials with disclaimers, no prescription, no provider, no follow-up. The risk isn't theoretical. Sterility, peptide identity, peptide content, and contamination all vary widely between gray-market vendors. The FDA has been explicit that compounded drugs aren't FDA-approved, and that research-only labels don't protect consumers when products end up in human use.
Oversight isn't a bureaucratic checkbox. It's a U.S.-licensed prescriber who reviews your history before prescribing, a 503A compounding pharmacy that sources active pharmaceutical ingredient and prepares the medication under USP 797 sterile standards, and a follow-up cadence that lets someone catch a problem before it becomes a worse one.
How Boswell handles this.
Boswell pairs you with a U.S.-licensed physician for the intake. They review your goals, medications, history, and any contraindications before prescribing. If a protocol isn't appropriate, you don't get it. If it is, the prescription goes to a 503A compounding pharmacy that prepares the medication under sterile compounding standards, labels it for you specifically, and ships it directly.
Refills aren't automatic — they involve a check-in. The point isn't to gate access; it's to keep someone clinical in the loop while you're on therapy. How Boswell works →
Questions worth asking your provider.
- Given the Phase IIb obesity trial didn't separate from placebo, what's the realistic expectation if I use AOD-9604?
- Does my history (thyroid, glucose tolerance, prior GLP-1 use) make me a poor or good candidate?
- How does AOD-9604 fit alongside my training, sleep, and protein intake — or does it?
- What signals would tell us this isn't working and we should stop?
- If I'm coming off a GLP-1, does AOD-9604 make sense in the rebuilding phase?
Sources